NewsDesk @bactiman63 The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus™ (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory...

NewsDesk @bactiman63 Nirsevimab is a long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly...

Sanofi has signed on December 10th a renewed partnership agreement with the World Health Organization (WHO), consolidating a 20-year collaboration to fight some of the most Neglected Tropical Diseases...

The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for MenQuadfiTM Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal...

In a follow-up on the Dengvaxia situation in the Philippines, the Food and Drug Administration (FDA) reports permanently revoking the Certificates of Product Registration (CPR) of dengue vaccine Dengvaxia...

Here are the top five posts on Outbreak News Today for the week Dec. 22 through Dec. 28: 5. Lyme bacteria persister forms, antibiotics and essential oils with Dr. Ying Zhang My interview with Dr Ying...

Global health care company, Sanofi, announced Wednesday that the US Food and Drug Administration (FDA) approved the pediatric hexavalent combination vaccine, VAXELIS™ . VAXELIS was developed as part...

The European Commission has granted marketing authorization for Dengvaxia®, Sanofi’s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines...

WHO understands that many people in the Philippines are concerned about dengue vaccination, following the release of new information about Dengvaxia® by the vaccine manufacturer released last week. The...

Dengvaxia manufacturer, the first dengue vaccine, Sanofi Pasteur announced that El Salvador has secured regulatory approval for the vaccine making it the fourth country to do so in the past two months. Dengvaxia...